LT3722310T - Stabilūs ir tirpūs antikūnai, slopinantys vegf - Google Patents

Stabilūs ir tirpūs antikūnai, slopinantys vegf

Info

Publication number
LT3722310T
LT3722310T LTEP20158159.2T LT20158159T LT3722310T LT 3722310 T LT3722310 T LT 3722310T LT 20158159 T LT20158159 T LT 20158159T LT 3722310 T LT3722310 T LT 3722310T
Authority
LT
Lithuania
Prior art keywords
stable
inhibit vegf
soluble antibodies
antibodies
soluble
Prior art date
Application number
LTEP20158159.2T
Other languages
English (en)
Lithuanian (lt)
Inventor
Leonardo Borras
David Urech
Tea Gunde
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3722310T publication Critical patent/LT3722310T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
LTEP20158159.2T 2008-06-25 2009-06-25 Stabilūs ir tirpūs antikūnai, slopinantys vegf LT3722310T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7569708P 2008-06-25 2008-06-25
US13321208P 2008-06-25 2008-06-25
US7569208P 2008-06-25 2008-06-25
US15504109P 2009-02-24 2009-02-24

Publications (1)

Publication Number Publication Date
LT3722310T true LT3722310T (lt) 2024-12-27

Family

ID=41209803

Family Applications (4)

Application Number Title Priority Date Filing Date
LTEP17151756.8T LT3216803T (lt) 2008-06-25 2009-06-25 Stabilūs ir tirpūs antikūnai, slopinantys vegf
LTEP09768693.5T LT2307454T (lt) 2008-06-25 2009-06-25 Stabilūs ir tirpūs antikūnai, slopinantys vegf
LTEP20158159.2T LT3722310T (lt) 2008-06-25 2009-06-25 Stabilūs ir tirpūs antikūnai, slopinantys vegf
LTPA2020004C LTC2307454I2 (lt) 2008-06-25 2020-07-23 Stabilūs ir tirpūs antikūnai, slopinantys VEGF

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LTEP17151756.8T LT3216803T (lt) 2008-06-25 2009-06-25 Stabilūs ir tirpūs antikūnai, slopinantys vegf
LTEP09768693.5T LT2307454T (lt) 2008-06-25 2009-06-25 Stabilūs ir tirpūs antikūnai, slopinantys vegf

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTPA2020004C LTC2307454I2 (lt) 2008-06-25 2020-07-23 Stabilūs ir tirpūs antikūnai, slopinantys VEGF

Country Status (26)

Country Link
US (6) US8349322B2 (enExample)
EP (3) EP2307454B1 (enExample)
JP (7) JP5956752B2 (enExample)
KR (8) KR102296443B1 (enExample)
CN (3) CN102143976B (enExample)
AU (1) AU2009264565C1 (enExample)
BR (1) BRPI0914251B1 (enExample)
CA (2) CA3020290A1 (enExample)
CL (1) CL2010001544A1 (enExample)
CY (3) CY1118829T1 (enExample)
DK (3) DK3216803T3 (enExample)
ES (3) ES2998307T3 (enExample)
FI (1) FI3722310T3 (enExample)
HR (3) HRP20170615T1 (enExample)
HU (4) HUE068894T2 (enExample)
LT (4) LT3216803T (enExample)
MX (3) MX347972B (enExample)
NL (1) NL301058I2 (enExample)
NO (1) NO2020021I1 (enExample)
PH (1) PH12015501593A1 (enExample)
PL (3) PL3216803T3 (enExample)
PT (3) PT3722310T (enExample)
RU (6) RU2531523C3 (enExample)
SI (3) SI3722310T1 (enExample)
WO (1) WO2009155724A2 (enExample)
ZA (1) ZA201008594B (enExample)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
AU2009264564B2 (en) 2008-06-25 2014-05-08 Novartis Ag Stable and soluble antibodies inhibiting TNFalpha
LT3216803T (lt) 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
SI2752428T1 (sl) 2008-06-25 2020-03-31 Novartis Ag Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa
KR101678925B1 (ko) * 2008-06-30 2016-11-24 에스바테크 - 어 노바티스 컴파니 엘엘씨 기능화 폴리펩티드
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
AU2010217120B2 (en) 2009-02-24 2014-11-20 Novartis Ag Methods for identifying immunobinders of cell-surface antigens
EP2445923B1 (en) 2009-06-22 2018-09-05 Amgen, Inc Refolding proteins using a chemically controlled redox state
MX2011013417A (es) 2009-06-25 2012-03-29 Amgen Inc Procesos de purificacion por captura para proteinas expresadas en un sistema no mamifero.
AU2011318567B2 (en) * 2010-10-19 2017-02-09 Mayo Foundation For Medical Education And Research Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
AR083495A1 (es) * 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CN108424449A (zh) * 2011-09-16 2018-08-21 Ucb医药有限公司 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
JP6184982B2 (ja) 2012-02-02 2017-08-23 エスバテック − ア ノバルティス カンパニー エルエルシー 点眼用抗体含有徐放性製剤
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
MX2015007931A (es) 2012-12-18 2015-10-05 Novartis Ag Composiciones y metodos que utilizan una etiqueta de peptido que se une a hialuronano.
CA2901226C (en) 2013-02-18 2020-11-17 Vegenics Pty Limited Vascular endothelial growth factor binding proteins
KR101541478B1 (ko) * 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
IL313351A (en) * 2013-06-26 2024-08-01 Numab Therapeutics AG New frameworks for antibodies
SG11201510315TA (en) 2013-07-12 2016-01-28 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
RU2702748C2 (ru) 2014-05-12 2019-10-11 Формикон Аг Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
KR102390359B1 (ko) 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
EP3218403B1 (en) 2014-11-10 2020-05-13 F.Hoffmann-La Roche Ag Anti-interleukin-33 antibodies and uses thereof
EP3250596A1 (en) * 2015-01-28 2017-12-06 Pfizer Inc Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
WO2016168757A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
US10851399B2 (en) * 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
EP3334842B1 (en) 2015-08-12 2022-03-02 Novartis AG Methods of treating ophthalmic disorders
EP3368578B1 (en) 2015-10-30 2021-03-17 H. Hoffnabb-La Roche Ag Anti-htra1 antibodies and methods of use thereof
JP7037148B2 (ja) * 2015-11-09 2022-03-16 国立大学法人京都工芸繊維大学 ヒト血清由来ＩｇＧポリクローナル抗体の分離剤、及び、それを用いたヒト血清由来ＩｇＧポリクローナル抗体を分離する方法
RU2734958C2 (ru) 2015-11-18 2020-10-26 Формикон Аг Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
EP3377151A1 (en) 2015-11-18 2018-09-26 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
MX382662B (es) 2015-11-18 2025-03-11 Sio2 Medical Products Inc Envase farmacéutico para formulaciones oftálmicas.
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
US11008387B2 (en) 2016-01-06 2021-05-18 Order-Made Medical Research Inc. Antibody inhibiting binding of VEGF to NRP1
JP6910963B2 (ja) 2016-01-06 2021-07-28 株式会社オーダーメードメディカルリサーチ 高親和性抗ｖｅｇｆ抗体
USD789171S1 (en) 2016-01-21 2017-06-13 Nomis Llc Right angle drive
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
WO2017136807A1 (en) * 2016-02-05 2017-08-10 The Board Of Regents Of The University Of Texas System Egfl6 specific monoclonal antibodies and methods of their use
WO2017156423A2 (en) * 2016-03-11 2017-09-14 Integrated Biotherapeutics, Inc. Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever
EP3222673A1 (de) * 2016-03-23 2017-09-27 LANXESS Deutschland GmbH Metallazopigmente
JP2019515671A (ja) 2016-04-15 2019-06-13 アルダー バイオファーマシューティカルズ、インコーポレイテッド 抗ｐａｃａｐ抗体及びそれらの使用
SI3479819T1 (sl) 2016-06-30 2024-06-28 Celltrion Inc. Stabilen tekoči farmacevtski pripravek
JP7050702B2 (ja) 2016-07-08 2022-04-08 ジェネンテック， インコーポレイテッド Ｎｒｆ２及びその遺伝子の下流標的遺伝子の発現状態及び変異状態によるがんの診断及び治療方法
CA3055256A1 (en) * 2017-03-09 2018-09-13 Mab Discovery Gmbh Antibodies specifically binding to human il-1r7
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
KR102607655B1 (ko) 2017-05-19 2023-11-28 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 리폴딩된 재조합 인간화 라니비주맙의 제조 방법
US20200171244A1 (en) 2017-05-24 2020-06-04 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
US20200237997A1 (en) 2017-05-24 2020-07-30 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
US20200157224A1 (en) * 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
EP3717636B1 (en) 2017-11-27 2023-03-08 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
CN111511400B (zh) 2017-12-29 2025-08-29 豪夫迈·罗氏有限公司 抗vegf抗体及其使用方法
US11078283B2 (en) 2018-01-17 2021-08-03 Apexigen, Inc. Anti-PD-L1 antibodies and methods of use
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
JP6938796B2 (ja) 2018-03-16 2021-09-22 ノバルティス アーゲー 眼疾患を治療するための方法
JP7574079B2 (ja) * 2018-04-06 2024-10-28 イーライ リリー アンド カンパニー 小児患者における癌の治療のためのラムシルマブ
JP7407822B2 (ja) 2018-08-30 2024-01-04 エイチシーダブリュー バイオロジックス インコーポレイテッド 単鎖キメラポリペプチドおよびその使用
EP4659757A2 (en) 2018-08-30 2025-12-10 ImmunityBio, Inc. Multi-chain chimeric polypeptides and uses thereof
CN112888445B (zh) 2018-08-30 2025-06-10 免疫生物公司 治疗老年化相关病症的方法
CN112672760B (zh) * 2018-09-13 2025-05-30 德克萨斯大学体系董事会 新颖lilrb4抗体和其用途
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
US11945859B2 (en) 2018-12-18 2024-04-02 Novartis Ag Protein solution formulation containing high concentration of an anti-VEGF antibody
USD907455S1 (en) 2019-05-21 2021-01-12 Nomis Llc Right angle drive attachment
USD907456S1 (en) 2019-05-21 2021-01-12 Nomis Llc Right angle drill attachment
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
KR20220062279A (ko) 2019-09-13 2022-05-16 노파르티스 아게 안질환의 치료 방법
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2023512827A (ja) * 2020-02-07 2023-03-29 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 抗原結合分子およびその使用
CN115362169A (zh) 2020-02-11 2022-11-18 Hcw生物科技公司 色谱树脂以及其用途
JP2023519107A (ja) 2020-02-11 2023-05-10 エイチシーダブリュー バイオロジックス インコーポレイテッド 制御性ｔ細胞を活性化する方法
WO2021163369A2 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
TW202146453A (zh) * 2020-02-28 2021-12-16 美商埃派斯進有限公司 抗sirpa抗體及其使用方法
CA3175140A1 (en) * 2020-03-12 2021-09-16 Immune-Onc Therapeutics, Inc. Novel anti-lilrb4 antibodies and derivative products
TW202144410A (zh) 2020-03-13 2021-12-01 美商建南德克公司 抗介白素－３３抗體及其用途
JP7734693B2 (ja) 2020-04-29 2025-09-05 イミュニティーバイオ インコーポレイテッド 抗ｃｄ２６タンパク質及びそれらの使用法
JP2023527869A (ja) 2020-06-01 2023-06-30 エイチシーダブリュー バイオロジックス インコーポレイテッド 加齢関連障害の治療法
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
MX2023000547A (es) * 2020-07-16 2023-02-13 Novartis Ag Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
EP4228706A1 (en) 2020-10-15 2023-08-23 Genentech, Inc. Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics
TW202237181A (zh) 2020-11-25 2022-10-01 瑞士商諾華公司 治療眼部疾病之方法
WO2022201084A1 (en) 2021-03-26 2022-09-29 Novartis Ag Methods for treating ocular diseases
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
KR102809807B1 (ko) 2021-12-21 2025-05-16 한림대학교 산학협력단 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
JP2025508939A (ja) 2022-03-02 2025-04-10 イミュニティーバイオ インコーポレイテッド 膵臓癌の治療方法
TW202337496A (zh) 2022-03-17 2023-10-01 瑞士商諾華公司 治療新生血管性年齡相關性黃斑點退化之方法
CN117820474A (zh) * 2023-04-25 2024-04-05 南京贝思奥生物科技有限公司 改善眼部血管新生相关疾病的药物及其应用
CN117069848B (zh) * 2023-08-02 2025-02-28 武汉爱博泰克生物科技有限公司 抗人cd146兔单克隆抗体及其应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
OA10149A (en) 1991-03-29 1996-12-18 Genentech Inc Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994010202A1 (en) 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
BRPI9707379B8 (pt) 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
ATE253593T1 (de) * 1996-07-16 2003-11-15 Plueckthun Andreas Prof Dr Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
WO2000053760A2 (en) * 1999-03-12 2000-09-14 Genentech, Inc. Method of preventing the death of retinal neurons and treating ocular diseases
US6986890B1 (en) 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
EP1695985B1 (en) * 1997-04-07 2011-03-09 Genentech, Inc. Methods for forming humanised antibodies by random mutagenesis
SI1325932T1 (enExample) * 1997-04-07 2005-08-31 Genentech Inc
WO2000034337A1 (en) 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
WO2000064946A2 (en) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
EP1233790A2 (en) 1999-10-22 2002-08-28 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products in cancer therapy
DK1242457T3 (da) 1999-12-28 2004-12-20 Esbatech Ag Intracellulære antistoffer [intracellulære antistoffer] med defineret struktur, der er stabil i et reducerende miljö, og anvendelse deraf
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
DE10201450B4 (de) 2002-01-16 2004-09-02 Infineon Technologies Ag Carry-Skip-Addierer für verschlüsselte Daten
US6576941B1 (en) 2002-02-20 2003-06-10 Samsung Electronics Co., Ltd. Ferroelectric capacitors on protruding portions of conductive plugs having a smaller cross-sectional size than base portions thereof
CN1187373C (zh) * 2002-03-20 2005-02-02 上海中信国健药业有限公司 人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
US8853362B2 (en) * 2002-05-22 2014-10-07 Esbatech, An Alcon Biomedical Research Unit Llc Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
EP1539947A4 (en) 2002-08-15 2006-09-06 Epitomics Inc HUMANIZED RABBIT ANTIBODIES
US20050186208A1 (en) 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
US20050048578A1 (en) * 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005044853A2 (en) * 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
WO2005016950A1 (en) * 2003-08-07 2005-02-24 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
JP5014130B2 (ja) 2004-08-02 2012-08-29 ズィナイス オペレーションズ ピーティーワイ．エルティーディー． Ｖｅｇｆ−ｂアンタゴニストを含む癌治療方法
PL1802334T3 (pl) 2004-10-21 2013-01-31 Genentech Inc Sposób leczenia wewnątrzgałkowych chorób neowaskularnych
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
RU2008110060A (ru) * 2005-08-15 2009-09-27 Арана Терапьютикс Лимитед (Au) Сконструированные антитела с каркасными участками приматов нового света
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2007140534A1 (en) * 2006-06-08 2007-12-13 Csl Limited Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling
CA2658241C (en) 2006-07-10 2018-01-02 Esbatech Ag Scfv antibodies which pass epithelial and/or endothelial layers
WO2008063932A2 (en) 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
US7553486B2 (en) 2006-11-13 2009-06-30 Paul Theodore Finger Anti-VEGF treatment for radiation-induced vasculopathy
SG10201503407WA (en) 2006-12-19 2015-06-29 Genentech Inc Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
US8280711B2 (en) 2007-03-12 2012-10-02 ESBATech, an Alcon Biomedical Research Unit, LLC. Sequence based engineering and optimization of single chain antibodies
JP2010528647A (ja) 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
MX2009013137A (es) 2007-06-06 2010-04-30 Domantis Ltd Metodos para seleccionar polipeptidos resistentes a la proteasa.
NZ581470A (en) 2007-06-25 2013-04-26 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
KR101573086B1 (ko) 2007-06-25 2015-11-30 에스바테크 - 어 노바티스 컴파니 엘엘씨 항체를 변형시키는 방법, 및 기능적 특성이 개선된 변형된 항체
CA2981887C (en) * 2008-03-26 2019-09-03 Epitomics, Inc. Anti-vegf antibody
LT3216803T (lt) * 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
SI2752428T1 (sl) * 2008-06-25 2020-03-31 Novartis Ag Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa
RU2514658C2 (ru) 2008-06-25 2014-04-27 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Оптимизация растворимости иммуносвязывающих средств
EP2769711A1 (en) * 2008-07-10 2014-08-27 ESBATech, an Alcon Biomedical Research Unit LLC Methods and Compositions for Enhanced Delivery of Macromolecules
JP5914353B2 (ja) * 2009-12-23 2016-05-11 エスバテック − ア ノバルティス カンパニー エルエルシー 免疫原性を減少させるための方法

Also Published As

Publication number Publication date
DK3216803T3 (da) 2020-06-02
WO2009155724A2 (en) 2009-12-30
KR20180098705A (ko) 2018-09-04
KR101671886B1 (ko) 2016-11-04
KR102013220B1 (ko) 2019-08-23
KR102095257B1 (ko) 2020-04-01
CA3020290A1 (en) 2009-12-30
CN110372792A (zh) 2019-10-25
JP6978468B2 (ja) 2021-12-08
JP2022020782A (ja) 2022-02-01
CN104961828A (zh) 2015-10-07
HUS2000028I1 (hu) 2020-08-28
EP2307454A2 (en) 2011-04-13
RU2696972C1 (ru) 2019-08-07
AU2009264565C1 (en) 2022-01-27
US20200172608A1 (en) 2020-06-04
KR102157097B1 (ko) 2020-09-18
KR20160128458A (ko) 2016-11-07
CY1118829T1 (el) 2018-01-10
ES2793008T3 (es) 2020-11-12
EP3216803B1 (en) 2020-03-11
HUE032894T2 (hu) 2017-11-28
PT2307454T (pt) 2017-04-26
LT2307454T (lt) 2017-05-25
JP7171877B2 (ja) 2022-11-15
HRP20241467T1 (hr) 2025-01-03
PH12015501593A1 (en) 2015-12-14
US20150274820A1 (en) 2015-10-01
EP2307454B1 (en) 2017-01-18
US20140004114A1 (en) 2014-01-02
CN102143976A (zh) 2011-08-03
KR20110028518A (ko) 2011-03-18
RU2531523C3 (ru) 2022-05-04
CL2010001544A1 (es) 2012-02-03
RU2648152C2 (ru) 2018-03-22
PT3722310T (pt) 2024-11-12
KR20170057462A (ko) 2017-05-24
HUE050230T2 (hu) 2020-11-30
AU2009264565B2 (en) 2014-05-08
JP5956752B2 (ja) 2016-07-27
DK2307454T3 (en) 2017-04-24
JP2018108081A (ja) 2018-07-12
RU2531523C9 (ru) 2015-04-10
JP6100199B2 (ja) 2017-03-22
HK1150844A1 (en) 2012-01-13
US10590193B2 (en) 2020-03-17
CY2020026I2 (el) 2020-11-25
RU2531523C2 (ru) 2014-10-20
LT3216803T (lt) 2020-06-10
JP2015134792A (ja) 2015-07-27
RU2747735C2 (ru) 2021-05-13
CA2727839C (en) 2018-11-20
SI2307454T1 (sl) 2017-05-31
US9873737B2 (en) 2018-01-23
EP3216803A1 (en) 2017-09-13
CY1123028T1 (el) 2021-10-29
JP6527128B2 (ja) 2019-06-05
RU2011102583A (ru) 2012-07-27
CY2020026I1 (el) 2020-11-25
PL3216803T3 (pl) 2020-10-19
ZA201008594B (en) 2012-02-29
HRP20170615T1 (hr) 2017-07-28
RU2016119152A (ru) 2017-11-21
NO2020021I1 (no) 2020-08-04
EP3722310A1 (en) 2020-10-14
KR20180005753A (ko) 2018-01-16
JP7171877B6 (ja) 2024-02-06
RU2014132888A (ru) 2015-12-10
KR102296443B1 (ko) 2021-09-01
US20120014958A1 (en) 2012-01-19
LTPA2020004I1 (lt) 2020-08-10
US20180072802A1 (en) 2018-03-15
RU2019120079A (ru) 2020-12-28
JP2017055774A (ja) 2017-03-23
KR101737466B1 (ko) 2017-05-18
HUE068894T2 (hu) 2025-02-28
US20250066462A1 (en) 2025-02-27
JP6821612B2 (ja) 2021-01-27
CA2727839A1 (en) 2009-12-30
CN102143976B (zh) 2015-11-25
RU2019120079A3 (enExample) 2020-12-28
RU2013133802A (ru) 2015-01-27
BRPI0914251B1 (pt) 2022-07-19
JP2011525359A (ja) 2011-09-22
EP3722310B1 (en) 2024-08-28
SI3722310T1 (sl) 2025-01-31
PT3216803T (pt) 2020-06-16
ES2998307T3 (en) 2025-02-19
LTC2307454I2 (lt) 2021-05-25
PL2307454T3 (pl) 2017-07-31
NL301058I1 (enExample) 2020-07-31
AU2009264565A1 (en) 2009-12-30
KR101817284B1 (ko) 2018-01-11
BRPI0914251A2 (pt) 2021-01-05
JP2014158491A (ja) 2014-09-04
US8349322B2 (en) 2013-01-08
KR20150132602A (ko) 2015-11-25
NL301058I2 (nl) 2020-10-27
US9090684B2 (en) 2015-07-28
ES2622470T3 (es) 2017-07-06
KR20200108922A (ko) 2020-09-21
MX347972B (es) 2017-05-22
PL3722310T3 (pl) 2025-01-20
CN104961828B (zh) 2019-03-26
KR20190092630A (ko) 2019-08-07
SI3216803T1 (sl) 2020-07-31
FI3722310T3 (fi) 2024-11-27
MX392435B (es) 2025-03-19
HRP20200814T1 (hr) 2020-08-07
JP2019162127A (ja) 2019-09-26
RU2588467C3 (ru) 2021-10-20
MX2011000011A (es) 2011-09-27
DK3722310T3 (da) 2024-11-18
RU2747735C3 (ru) 2022-05-04
WO2009155724A3 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
LTPA2020004I1 (lt) Stabilūs ir tirpūs antikūnai, slopinantys VEGF
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
NO2021006I1 (no) Quofenix, delafloksacin
BRPI0912173A2 (pt) anticorpos anti-flt3
DK3072906T3 (da) Antistofformulering
EP2358392A4 (en) ANTIBODY FORMULATION
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB
BRPI0909633A2 (pt) anticorpos anti-tyrp1
BRPI0912769A2 (pt) anticorpos anti-pirb
ES1076487Y (es) Dispositivo de hojas correderas batientes.
BRPI0922477A2 (pt) transportador.
IT1396642B1 (it) Statore.
NL2002394A1 (nl) Parasolinrichting.
NL2002599A1 (nl) Hoogwerker.
BRPI1007268A2 (pt) Combinações pesticidas.
NL1037357C2 (nl) Klimatisatie-inrichting.
IT1398344B1 (it) Dispositivo dosatore perfezionato.
NL2001911A1 (nl) Hijsinrichting.
NL1035121A1 (nl) Verbindingsorgaan, mobiele veilige houder en combinatie daarvan.
NL2002090C (nl) Bindinrichting.
FR2935319B1 (fr) Fourgonnette amenagee.
NL1036071C (nl) Zelfperforerende ordner.
ITRM20080260A1 (it) Quadriciclo.